单灶低危甲状腺微小乳头状癌射频消融的长期结局:414例大样本队列研究
本研究纳入2014年6月至2017年12月经粗针活检确诊的414例单灶低危甲状腺微小乳头状癌患者,接受射频消融治疗并长期随访。平均随访42.15±11.88个月,肿瘤体积由92.74±83.43 mm³降至1.37±7.94 mm³,平均体积缩小率98.81±6.41%,88.41%肿瘤完全消失,局部肿瘤进展率3.62%,无危及生命或迟发并发症。
要点
- 射频消融后平均随访42.15个月,平均体积缩小率98.81%,88.41%肿瘤完全消失。
- 局部肿瘤进展率3.62%,其中残留癌0.24%、转移性淋巴结0.97%、复发PTMC 2.42%。
- 无危及生命或迟发并发症发生。
关键影像表现/征象
- 超声及超声造影随访显示肿瘤平均初始体积92.74±83.43 mm³(范围4.19-490.07 mm³),末次随访降至1.37±7.94 mm³(范围0-67.97 mm³)。
- 414例中366个肿瘤(88.41%)完全消失。
诊断标准与关键数值
- 平均随访42.15±11.88个月(范围24-69个月),平均体积缩小率98.81±6.41%(范围50-100%)。
- 局部肿瘤进展总发生率3.62%,其中1例(0.24%)经粗针活检诊断为残留癌并追加射频消融。
- 4例(0.97%)出现转移性淋巴结,10例(2.42%)复发甲状腺微小乳头状癌。
- 共13例接受追加射频消融,随访中11个病灶完全消失。
临床应用与阅片要点
- 对严格筛选的低危甲状腺微小乳头状癌,射频消融可作为有效且安全的替代治疗选择。
- 随访采用超声和超声造影,于术后1、3、6、12个月及之后每6-12个月评估体积和体积缩小率。
- 需关注局部肿瘤进展、残留癌、转移性淋巴结及复发,必要时追加射频消融。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to evaluate the long-term efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population.
METHODS: From June 2014 to December 2017, 414 patients (323 females, 91 males, mean age 43.56 ± 9.79 years, range 18-73 years) with unifocal low-risk PTMC confirmed by core-needle biopsy (CNB) were treated by RFA. Patients were followed up at 1, 3, 6, and 12 months and every 6-12 months thereafter by ultrasound and contrast-enhanced ultrasound (CEUS). The volume and the volume reduction ratio (VRR) were calculated. Recurrence and lymph node or distant metastasis were evaluated.
RESULTS: The mean initial volume was 92.74 ± 83.43 mm3 (range 4.19-490.07 mm3), which decreased significantly to 1.37 ± 7.94 mm3 (range 0-67.97 mm3) at a mean follow-up time of 42.15 ± 11.88 months (range 24-69 months) with a mean VRR of 98.81 ± 6.41% (range 50-100%). No life-threatening or delayed complications occurred. After RFA, 366 tumors (88.41%) completely disappeared. The overall incidence of local tumor progression rate was 3.62%. Among them, one patient (0.24%) was diagnosed to have residual cancer by CNB and underwent additional RFA. Four patients (0.97%) developed metastatic lymph node, and 10 patients (2.42%) had recurrent PTMC. A total of 13 patients underwent additional RFA, and 11 lesions completely disappeared during the follow-up.
CONCLUSIONS: RFA is an effective and safety treatment for low-risk PTMC after a long-term follow-up period for a large cohort with careful patient enrollment evaluation.
KEY POINTS: • Radiofrequency ablation is an effective and safe alternative for low-risk PTMC. • The overall incidence of local tumor progression rate was low. • No life-threatening or delayed complications occurred.
引用
- Yan L, Lan Y, Xiao J, et al. Long-term outcomes of radiofrequency ablation for unifocal low-risk papillary thyroid microcarcinoma: a large cohort study of 414 patients. Eur Radiol. 2020. PMID: 32813103. doi:10.1007/s00330-020-07128-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。